Induction involves Erk1/2-dependent activation of scaling factors Arc and Homer1a and subsequent activation of ligand-independent signaling from mGluR1/5 within 1–12 h of BCC treatment (Hu et al., 2010; Bateup et al., 2013). This evidence concerns the gene MAPK3 and skin basal cell carcinoma.